USPTO serial 88314433
PAPA & BARKLEY RELEAF
Reviewed by CopyMark Law Group
Status 605
- Filing date
- Status date
- Registration date
- —
- Examiner
- SALES, HEATHER ALISON
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with PAPA & BARKLEY RELEAF?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kamran Fattahi
Kamran Fattahi Law Offices of Kamran Fattahi15303 Ventura Blvd., Suite 900Sherman Oaks, CA 91403United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 003 | Essential oils for cosmetic purposes, all the foregoing containing cannabis ingredients solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; Essential oils for cosmetic purposes, all the foregoing containing cannabinoids solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; Cosmetics, all the foregoing containing cannabis ingredients solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; Cosmetics, all the foregoing containing cannabinoids solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; Cosmetics, namely, non-medicated body oils, all the foregoing containing cannabis ingredients solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; Cosmetics, namely, non-medicated body oils, all the foregoing containing cannabinoids solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; Cosmetics, namely, non-medicated body oils in drop form, capsule form, and liquid form, all the foregoing containing cannabis ingredients solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; Cosmetics, namely, non-medicated body oils in drop form, capsule form, and liquid form, all the foregoing containing cannabinoids solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; Cosmetics, namely, non-medicated body ointments, all the foregoing not intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, all the foregoing containing cannabis ingredients solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; Cosmetics, namely, non-medicated body ointments, all the foregoing not intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, all the foregoing containing cannabinoids solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; Cosmetics, namely, non-medicated body ointments in drop form and liquid form, all the foregoing not intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, all the foregoing containing cannabis ingredients solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; Cosmetics, namely, non-medicated body ointments in drop form and liquid form, all the foregoing not intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, all the foregoing containing cannabinoids solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; Non-medicated body soaks, all the foregoing containing cannabis ingredients solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; Nonmedicated body soaks, all the foregoing containing cannabinoids solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; Electronic cigarette liquid (e-liquid) comprised of essential oils, all the foregoing containing cannabis ingredients solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; Electronic cigarette liquid (e-liquid) comprised of essential oils, all the foregoing containing cannabinoids solely derived from Cannabis sativa L. with a delta9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis | ABANDONED | — |
| 005 | Orally-ingestible nutritional supplements in drop form, capsule form, and liquid form, all the foregoing containing cannabis ingredients solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Orally-ingestible nutritional supplements in drop form, capsule form, and liquid form, all the foregoing containing cannabichromene solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Orally-ingestible nutritional supplements in drop form, capsule form, and liquid form, all the foregoing containing cannabielsoin solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Orally-ingestible nutritional supplements in drop form, capsule form, and liquid form, all the foregoing containing cannabinol solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Orally-ingestible nutritional supplements in drop form, capsule form, and liquid form, all the foregoing containing cannabinodiol solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Orally-ingestible nutritional supplements in drop form, capsule form, and liquid form, all the foregoing containing cannabidiol solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Orally-ingestible nutritional supplements in drop form, capsule form, and liquid form, all the foregoing containing cannabicitran solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Orally-ingestible nutritional supplements in drop form, capsule form, and liquid form, all the foregoing containing cannabimovone solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Orally-ingestible herbal tinctures for medicinal purposes in the nature of nutritional and dietary supplements, all the foregoing containing cannabis ingredients solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Orally-ingestible herbal tinctures for medicinal purposes in the nature of nutritional and dietary supplements, all the foregoing containing cannabichromene solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Orally-ingestible herbal tinctures for medicinal purposes in the nature of nutritional and dietary supplements, all the foregoing containing cannabielsoin solely derived from Cannabis sativa L. with a delta9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Orally-ingestible herbal tinctures for medicinal purposes in the nature of nutritional and dietary supplements, all the foregoing containing cannabinol solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Orally-ingestible herbal tinctures for medicinal purposes in the nature of nutritional and dietary supplements, all the foregoing containing cannabinodiol solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Orally-ingestible herbal tinctures for medicinal purposes in the nature of nutritional and dietary supplements, all the foregoing containing cannabidiol solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Orally-ingestible herbal tinctures for medicinal purposes in the nature of nutritional and dietary supplements, all the foregoing containing cannabicitran solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Orally-ingestible herbal tinctures for medicinal purposes in the nature of nutritional and dietary supplements, all the foregoing containing cannabimovone solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Orally-ingestible nutritional and dietary supplements in the form of capsules, pills, liquids, tablets, powders, extracts, and tinctures, for use in acting upon or caring for stress, loss of appetite, anxiety, fatigue, wellbeing, and mood enhancement, all the foregoing containing cannabis ingredients solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Orally-ingestible nutritional and dietary supplements in the form of capsules, pills, liquids, tablets, powders, extracts, and tinctures, for use in acting upon or caring for stress, loss of appetite, anxiety, fatigue, wellbeing, and mood enhancement, all the foregoing containing cannabichromene solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Orally-ingestible nutritional and dietary supplements in the form of capsules, pills, liquids, tablets, powders, extracts, and tinctures, for use in acting upon or caring for stress, loss of appetite, anxiety, fatigue, wellbeing, and mood enhancement, all the foregoing containing cannabielsoin solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Orally-ingestible nutritional and dietary supplements in the form of capsules, pills, liquids, tablets, powders, extracts, and tinctures, for use in acting upon or caring for stress, loss of appetite, anxiety, fatigue, wellbeing, and mood enhancement, all the foregoing containing cannabinol solely derived from Cannabis sativa L. with a delta9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Orally-ingestible nutritional and dietary supplements in the form of capsules, pills, liquids, tablets, powders, extracts, and tinctures, for use in acting upon or caring for stress, loss of appetite, anxiety, fatigue, wellbeing, and mood enhancement, all the foregoing containing cannabinodiol solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Orally-ingestible nutritional and dietary supplements in the form of capsules, pills, liquids, tablets, powders, extracts, and tinctures, for use in acting upon or caring for stress, loss of appetite, anxiety, fatigue, wellbeing, and mood enhancement, all the foregoing containing cannabidiol solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Orally-ingestible nutritional and dietary supplements in the form of capsules, pills, liquids, tablets, powders, extracts, and tinctures, for use in acting upon or caring for stress, loss of appetite, anxiety, fatigue, wellbeing, and mood enhancement, all the foregoing containing cannabicitran solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Orally-ingestible nutritional and dietary supplements in the form of capsules, pills, liquids, tablets, powders, extracts, and tinctures, for use in acting upon or caring for stress, loss of appetite, anxiety, fatigue, wellbeing, and mood enhancement, all the foregoing containing cannabimovone solely derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, and none of foregoing featuring more than trace amounts of cannabidiol; Specialized tablets, capsules and powders for the delivery of pharmaceuticals sold without the pharmaceutical ingredient, all of the foregoing containing no cannabis and no cannabinoids | ABANDONED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Egg Rock Holdings, LLC
- Other trademarks owned by Egg Rock Holdings, LLC
- Other trademarks owned by MAMMOTH MANAGEMENT, INC.
- Other trademarks in Class 003
- Other trademarks in Class 005
- Similar marks named PAPA & BARKLEY RELEAF
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 24, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 24, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 24, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 24, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Nov 24, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Feb 20, 2025 | MAB5 | ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION | — |
| Feb 20, 2025 | ABN5 | ABANDONMENT - AFTER PUBLICATION | — |
| Feb 19, 2025 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| Feb 5, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 13, 2024 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Sep 13, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 13, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 13, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 13, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Sep 13, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 29, 2024 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jul 8, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 8, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jul 8, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jul 8, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 20, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 26, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 26, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 6, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 21, 2023 | EXPT | EXPARTE APPEAL TERMINATED | — |
| Nov 21, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 3, 2023 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Feb 25, 2023 | GEA1 | NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED | — |
| Feb 25, 2023 | GECD | ACTION DENYING REQ FOR RECON E-MAILED | — |
| Feb 25, 2023 | CNCF | ACTION CONTINUING FINAL - COMPLETED | — |
| Oct 20, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 20, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 20, 2022 | ALIE | ASSIGNED TO LIE | — |
| Oct 14, 2022 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jul 5, 2022 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Apr 14, 2022 | GNS1 | NOTIFICATION OF SUBSEQUENT FINAL EMAILED | — |
| Apr 14, 2022 | GNSF | SUBSEQUENT FINAL EMAILED | — |
| Apr 14, 2022 | CFRC | SUBSEQUENT FINAL REFUSAL WRITTEN | — |
| Oct 23, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 22, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 22, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 26, 2021 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 26, 2021 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 26, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 4, 2021 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Jan 4, 2021 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Dec 15, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 15, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 15, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 14, 2020 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Dec 14, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 14, 2020 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Dec 14, 2020 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Dec 14, 2020 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Dec 14, 2020 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| Dec 14, 2020 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Dec 14, 2020 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Dec 13, 2020 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jun 13, 2020 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jun 13, 2020 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 13, 2020 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 12, 2020 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| May 11, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| May 11, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 4, 2020 | ALIE | ASSIGNED TO LIE | — |
| Apr 29, 2020 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Apr 29, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 29, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 29, 2020 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Oct 29, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 29, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 29, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 28, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| May 6, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| May 6, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 21, 2019 | MDSM | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Mar 15, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 28, 2019 | NWAP | NEW APPLICATION ENTERED | — |